• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Macrolide Plus Nucleoside Combo Curbs SARS-CoV-2 and Shields Monkey Lungs

by
October 6, 2026
in Health
Reading Time: 4 mins read
0
Macrolide Plus Nucleoside Combo Curbs SARS-CoV-2 and Shields Monkey Lungs

Macrolide Plus Nucleoside Combo Curbs SARS-CoV-2 and Shields Monkey Lungs

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A combination of the macrolide antibiotic Carrimycin and the nucleoside analogue Azvudine suppressed SARS-CoV-2 replication more effectively than either drug alone in rhesus macaques, while also easing lung injury and correcting immune dysregulation, according to a study published in the Journal of Translational Medicine. The work, led by researchers at the Chinese Academy of Medical Sciences and Peking Union Medical College, addresses a persistent gap in COVID-19 therapeutics: most current antivirals target viral replication alone and offer little protection against the immunoinflammatory damage that drives severe disease.

The rationale for the combination rests on the complementary profiles of the two drugs. Azvudine, known chemically as FNC, is a nucleoside reverse transcriptase inhibitor approved in China for HIV treatment and later authorized for COVID-19. As an analogue, it is incorporated by viral polymerases and terminates RNA synthesis, acting directly on the SARS-CoV-2 RNA-dependent RNA polymerase. Carrimycin, by contrast, is a macrolide derived from the engineered antibiotic compound 4″-O-isovalerylspiramycin. Macrolides are best known as antibacterials, but several members of the class display immunomodulatory and anti-inflammatory properties, and Carrimycin has previously shown antiviral activity against coronaviruses. Pairing a direct-acting polymerase inhibitor with an agent that modulates host responses is an appealing strategy precisely because evolving SARS-CoV-2 variants have begun to erode the effectiveness of replication-targeted monotherapy.

To test the concept, the team turned to rhesus macaques, which remain among the most faithful animal models of human COVID-19 because they develop viral pneumonia, radiographic abnormalities, and immune responses that closely mirror clinical disease. Animals were inoculated intratracheally with SARS-CoV-2 and then treated orally for seven days with Carrimycin at 9 milligrams per kilogram, Azvudine at 0.07 milligrams per kilogram, or the two drugs together. The researchers then tracked viral loads, lung pathology, immune responses, and gut microbiota across the treatment groups, conducting the work in an animal biosafety level 3 facility under protocols approved by the institutional animal care committee.

The antiviral results were clear-cut. Both monotherapies significantly inhibited SARS-CoV-2 replication, but the combination produced additive effects, driving viral loads down further in both throat swabs and lung tissue. That pattern matters because viral burden in the lower respiratory tract correlates with disease severity and onward transmission risk. Notably, the authors reported no significant side effects in the treated animals, an important consideration for a combination intended for clinical use, since drug-drug interactions and cumulative toxicity often limit real-world combination regimens.

Lung protection was assessed by chest imaging and histopathology, and here the combination again outperformed either drug alone. Monotherapy reduced ground-glass opacities, the hazy areas on chest scans that reflect fluid and inflammatory infiltration of lung tissue, and mitigated focal interstitial pneumonia, the inflammation of the tissue between air sacs that characterizes severe COVID-19. The combination treatment demonstrated superior efficacy on both measures, suggesting that blunting viral replication while simultaneously damping host inflammation preserves lung architecture more effectively than either intervention alone.

To understand how the combination reshaped the lung environment, the researchers performed transcriptomic profiling and immunofluorescence staining of lung tissue. Gene expression analysis revealed enhanced immunomodulation under combination therapy, including suppression of neutrophil degranulation, a process in which activated neutrophils release enzymes and antimicrobial proteins that, when excessive, damage surrounding tissue and contribute to acute lung injury. The combination also increased populations of CD19-positive B cells and CD3-positive T cells, the cornerstones of adaptive humoral and cellular immunity, while decreasing CD68-positive macrophages, whose accumulation in the lung is associated with sustained inflammation.

At the molecular level, combination therapy downregulated pro-inflammatory and apoptotic markers, pointing to reduced inflammatory signaling and less programmed cell death in infected lung tissue. Taken together, these findings suggest the combination does more than lower viral numbers; it shifts the lung immune landscape away from the maladaptive innate hyperinflammation seen in severe COVID-19 and toward a more effective adaptive response. That distinction is clinically significant, because mortality in severe COVID-19 is driven as much by immunopathology as by the virus itself, and therapies that address both axes have been sought since the beginning of the pandemic.

The study also uncovered a difference between the two drugs that monotherapy comparisons alone would have missed. Carrimycin, but not Azvudine, increased gut bacteria that produce short-chain fatty acids, metabolites with well-documented anti-inflammatory and immune-regulatory effects, and decreased harmful pathogens previously associated with COVID-19 progression. The gut-lung axis, the bidirectional communication between intestinal microbes and respiratory immunity, has emerged as a contributor to COVID-19 outcomes, and dysbiosis has been linked to worse disease. A drug that simultaneously acts on the lung and restores a favorable microbiome composition could therefore offer benefits beyond direct antiviral activity, potentially supporting recovery and reducing secondary complications.

The authors conclude that the Carrimycin-Azvudine combination showed superior efficacy in suppressing viral replication, alleviating lung injury, and correcting immune and inflammatory dysregulation, with Carrimycin providing additional gut microbiota benefits. They position the pairing as a promising therapeutic strategy against COVID-19 and its complications, particularly in a landscape where ongoing viral mutation, emerging resistance mutations, inadequate immunomodulation, and suboptimal organ protection limit existing antiviral options. The work was supported by the National Natural Science Foundation of China, the National Key Research and Development Program of China, and the CAMS Innovation Fund for Medical Sciences.

As with any preclinical animal study, the path from macaques to patients requires clinical validation, including pharmacokinetic confirmation of the doses used, human safety data for the combination, and efficacy trials in infected populations. Nevertheless, the study offers a mechanistically grounded template for next-generation COVID-19 therapy: a direct-acting antiviral paired with an immunomodulatory and microbiome-friendly partner, evaluated with the full toolkit of modern virology, imaging, transcriptomics, and metagenomics. If the additive antiviral and lung-protective effects observed here translate to humans, the combination could address precisely the shortcomings, resistance, inflammation, and organ damage, that have constrained single-drug approaches throughout the pandemic.

Subject of Research: Combination antiviral therapy with Carrimycin and Azvudine against SARS-CoV-2 infection in rhesus macaques

Article Title: Better antiviral and lung-protective effects of Carrimycin in combination with Azvudine in rhesus macaques infected with SARS-CoV-2

Article References: Li, H., Liu, Y., Xue, J., Li, J., Xu, J., Dong, B., Wang, T., Peng, X., Che, Y., Jiang, J., & Peng, Z. (2026). Better antiviral and lung-protective effects of Carrimycin in combination with Azvudine in rhesus macaques infected with SARS-CoV-2. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08933-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08933-1

Keywords: SARS-CoV-2, Carrimycin, Azvudine, combination therapy, rhesus macaques, lung injury, immunoinflammatory regulation, gut microbiota, antivirals, macrolides, COVID-19, translational medicine

News Source: Ophelia Keating. (October 6, 2026). Macrolide Plus Nucleoside Combo Curbs SARS-CoV-2 and Shields Monkey Lungs. Scienmag.

Tags: antiviralsAzvudineCarrimycincombination therapyCOVID-19gut microbiotaimmunoinflammatory regulationlung injurymacrolidesrhesus macaquesSARS-CoV-2translational medicine
Share12Tweet7Share2ShareShareShare1

Related Posts

Augmented Reality Navigation Shows Feasibility in Pilot Brain Biopsy Study

Augmented Reality Navigation Shows Feasibility in Pilot Brain Biopsy Study

November 20, 2026
Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors

Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors

November 20, 2026

Structured Mental Health Training Boosts Clinical Skills Among Nigerian Healthcare Workers

November 20, 2026

Transient Brain Network Disruption Marks Internet Gaming Disorder During Resting Scans

November 20, 2026

POPULAR NEWS

  • Pediatric Urology AI Prediction Models Lack External Validation Despite High Discrimination

    Pediatric Urology AI Prediction Models Lack External Validation Despite High Discrimination

    29 shares
    Share 12 Tweet 7
  • Ultraviolet-Ozone Fabric Treatment Boosts 3D-Printed Polymer Adhesion by Up to 239 Percent

    29 shares
    Share 12 Tweet 7
  • Rapid Review Identifies Thirty-Eight Parent-of-Origin Genetic Variants Linked to Fetal Growth

    29 shares
    Share 12 Tweet 7
  • Breeding Failure Prompts Earlier Autumn Migration in Southern British Eurasian Curlews

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Augmented Reality Navigation Shows Feasibility in Pilot Brain Biopsy Study

Displacement Functional Minimization Establishes Meir–Keeler Fixed Points Without Space Completeness

Bronchiectasis Affects Over a Quarter of Patients With Inborn Immune Errors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.